



CareDx Files Registration Statement for Proposed Initial Public Offering

Brisbane, Calif. – June 3, 2014 – CareDx, Inc., announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

Piper Jaffray & Co. and Leerink Partners LLC are acting as joint book-running managers for the proposed offering. Raymond James & Associates, Inc. and Mizuho Securities USA Inc. are acting as co-managers for the proposed offering.

The offering will be made only by means of a prospectus. When available, a copy of the prospectus may be obtained from the offices of Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com; or Leerink Partners LLC, 201 Spear St., 16th Floor, San Francisco, CA 94105 or by telephone at (800) 778-1164.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CareDx, Inc.

CareDx is a commercial stage company that develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a patient's lifetime. Its commercialized testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a blood-based test used to monitor heart transplant recipients for acute cellular rejection. CareDx is seeking to apply its expertise in heart transplantation towards the development of additional solutions for organ transplant recipients, including recipients of heart and kidney transplants.